Clinical trials: Secondary Stroke

Stroke

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

• Terminated
• Age: 50 years and older
• Phase 3
• Results posted

This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.

Trial name

NAVIGATE ESUS (NCT02313909)

Testing

Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)

Where

454 sites in United States, Argentina and 29 more

Volunteers

7,213 people

Sponsor

Bayer